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Abstract
Excitatory neurons are preferentially impaired in early Alzheimer’s disease but the pathways 
contributing to their relative vulnerability remain largely unknown. Here we report that 
pathological tau accumulation takes place predominantly in excitatory neurons compared to 
inhibitory neurons, not only in the entorhinal cortex, a brain region affected in early Alzheimer’s 
disease, but also in areas affected later by the disease. By analyzing RNA transcripts from single-
nucleus RNA datasets, we identified a specific tau homeostasis signature of genes differentially 
expressed in excitatory compared to inhibitory neurons. One of the genes, BCL2 associated 
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athanogene 3BAG3, a facilitator of autophagy, was identified as a hub or master regulator, gene. 
We verified that reducing BAG3 levels in primary neurons exacerbated pathological tau 
accumulation whereas overexpression attenuated it. These results support the conclusion that tau 
homeostasis underlies the cellular and regional vulnerability of excitatory neurons to tau 
pathology.
Life Science Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary 
linked to this article.
Main
Neurodegenerative disorders are characterized by the accumulation of pathological proteins 
and the progressive loss of specific neuronal cell populations. The accumulation of 
misfolded tau aggregates is a defining feature of Alzheimer’s disease (AD) and 
Frontotemporal lobar degeneration linked to tau (FTLD-tau)1–3. Several types of neurons 
have been reported to be particularly vulnerable in AD4–9, Down’s syndrome10 and 
FTLD2, 3, 11. The distribution of neurons vulnerable to tauopathy follows a sequential 
pattern that suggests that cell populations in different regions of the brain are selectively at 
risk. More specifically, the morphology and location of cells within the EC and 
hippocampus that accumulate tau and degenerate in the earliest stages of AD suggest that 
EX neurons are preferentially impacted4, 12. Previous studies have addressed the question of 
why putative EX neurons could be particularly vulnerable to degeneration in aging, AD and 
other neurodegenerative disorders6, 13–15. Determinants of neuronal vulnerability might 
include cell size and location within neural circuits, signaling pathways controlling 
excitation, mechanisms regulating calcium and energy homeostasis, metabolism of disease-
specific proteins, repertoires of signal transduction pathways and stress resistance 
mechanisms, and protein homeostasis dysfunction16–19. However, the exact molecular 
determinants underlying the selective vulnerability of EX neurons to tau pathology have not 
been established.
To explore these determinants, we employed four complementary approaches. First, using a 
series of cell-type specific markers on AD patient brains and a mouse model of tauopathy20 
we showed that tau co-localizes predominantly with EX, compared to IN, neuron markers, 
not only in the EC but also in areas affected later in the disease such as the neocortex4. 
Second, using single-nucleus RNA-seq datasets from normal donors, we identified a 
significant difference between EX and IN neurons in genes involved in a branch of the 
protein homeostasis system that modulates the aggregation and clearance of tau. Third, using 
the weighted gene co-expression network analysis, we identified that BAG3, a putative 
aggregation protector21, 22, is a hub gene in the co-expression network relevant to tau 
homeostasis. Lastly, we confirmed that BAG3 is differentially expressed in human EX and 
IN neurons in non-AD and AD cases, and it impacts tau accumulation in primary neurons. 
Taken together, these results support the conclusion that tau homeostasis contributes to the 
selective, regional vulnerability of EX neurons to tau pathology and cell loss that defines 
AD, and they suggest that dysregulation of specific branches of the protein homeostasis 
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system plays an important role in the initiation and spread of tau pathology in AD and the 
primary tauopathies.
Results
Excitatory and inhibitory neurons are differentially vulnerable to tau pathology in primary 
and secondary affected regions of EC-tau mice
Tau species recognized by human-specific antibodies such as MC1 (which targets misfolded 
tau) were co-localized with EX neuronal markers (TBR1 and SATB2), but there was almost 
no co-localization with IN neuronal markers (PVALB, SST and CALB2) in layers II-IV of 
the medial entorhinal cortex (MEC), perirhinal cortex (PRH) and neocortex (NC) of EC-tau 
mice20 at either 22 or 30+ months of age (Fig. 1a-c; Supplementary Fig. 1). These results are 
consistent with the observation of limited co-localization of human tau with IN neurons in 
the dentate gyrus of this mouse model23. In addition to being differentially vulnerable to 
pathological tau accumulation, EX neurons in the MEC were also differentially vulnerable 
to cell loss. The number of EX neurons was significantly reduced in the MEC, but not in the 
PRH or NC regions of EC-tau mice at 30+ months compared with 22 months (Fig. 1d). 
However, there was no significant difference in the number of IN neurons in EC-tau mice at 
30+ months compared with 22 months (Fig. 1d). The number of MC1+ neurons was also 
significantly reduced in the MEC of EC-tau mice at 30+ months compared with 22 months 
(Fig. 1e), most likely due to the dramatic loss of EX neurons in that region (Fig. 1d). There 
was no significant difference in the number of EX neurons in non-transgenic (WT) mice 
between 22 months and 30+ months (Fig. 1f) indicating that the loss of EX neurons was not 
associated with aging, but with the maturation of tau pathology in the MEC. The increased 
number of MC1+ neurons in the PRH and NC of EC-tau mice at 30+ months (Fig. 1e) 
indicates the propagation and spreading of tau pathology from the primary to the secondary 
affected areas of the neocortex. Taken together, these results demonstrate that EX neurons 
are vulnerable to both the accumulation and the propagation of tauopathy in this mouse 
model of tauopathy.
EX and IN human neurons are differentially vulnerable to tau pathology in primary and 
secondary affected regions of AD brain
In order to explore whether or not pathological tau also differentially impacts human EX 
neurons in AD, we performed co-localization studies on post-mortem brain tissues at 
different stages of AD assessed by the Braak staging protocol4. Consistent with the mouse 
data, we found that MC1+ tau pathology was mainly co-localized with EX neuronal 
markers, but not IN neurons in layers II-IV of the EC and in secondary affected regions such 
as the prefrontal cortex (Brodmann area 9, BA9) at early and late Braak stages (Fig. 2a-c; 
Supplementary Fig. 2). Moreover, the number of EX neurons was significantly reduced in 
the mid-late stage AD brain (Braak stages III-IV and V-VI) compared with non-AD controls 
(Braak stages I-II) (Fig. 2d, e). Tau pathology was not evident in microglia (IBA1+) or 
astrocytes (GFAP+). The co-localization of pathological forms of tau with neuronal markers 
in both EC-tau mice and human AD was further confirmed with phosphorylation-site 
specific tau antibodies. Consistent with the MC1 data, we found that EX neurons (SATB2+), 
but not IN neurons (GAD1+), co-localized with phospho-tau specific antibodies including 
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AT8 (Ser202/Thr205), PHF1 (Ser396/Ser404), pS422-Tau (Ser422), and AT100 (Thr212/
Ser214) (Supplementary Fig. 3). Overall, these data suggest that in human brains EX and IN 
neurons are differentially vulnerable to tau pathology in primary and secondary affected 
regions in AD. This conclusion is also consistent with previous reports of the selective 
vulnerability of pyramidal neurons in AD4, 6, 12.
Single-nucleus RNA-seq analysis reveals a specific tau homeostasis signature in EX 
neurons in the human brain
We hypothesized that the selective vulnerability of EX neurons to tau pathology could be 
determined by an intrinsic difference in the cellular environment in terms of the specific 
branch of the protein homeostasis system that regulates tau aggregation. To test this idea and 
to begin to identify this ‘tau homeostasis system’, we analyzed two independent single-
nucleus RNA-seq datasets obtained from post-mortem brain tissues of healthy adults without 
AD pathology24, 25. We found that the mRNA levels of genes encoding the proteins making 
up a metastable subproteome (MS)26, and tau co-aggregators and aggregation promoters19 
were increased, but the mRNA levels of tau aggregation protector genes19 were decreased in 
EX neurons compared with IN neurons. Furthermore, differential expression of the tau 
homeostasis genes was seen in regions affected early (BA21 including EC, BA22, BA10, 
BA41; Hippocampus) and late (BA17; BA9) in AD (Fig. 3a-d; Supplementary Table 1, and 
Supplementary Figs. 4 and 5). Overall, a statistically significant and consistent pattern 
emerged from the analysis of the two datasets indicating that genes encoding proteins 
involved in tau homeostasis (tau aggregation promoters and protectors, and tau co-
aggregators) and proteins in the MS were differentially regulated in cells that are vulnerable 
to tauopathy compared to those that are resistant to it. Taken together (Supplementary Fig. 
6), these results indicate that dysregulated tau homeostasis is closely linked to the etiology 
of tauopathy.
Glial cells have higher levels of aggregation protectors than neurons
We observed that the subproteomes most relevant to tau homeostasis show a specific 
signature for neurons compared to glial cell types (microglia, oligodendrocytes and 
astrocytes). Overall, we observed statistically significant increased mRNA levels of genes 
protecting from tau aggregation in glia cells, which was combined with relatively low level 
expression of tau, together with low mRNA levels of genes promoting tau aggregation, and 
encoding its co-aggregators (Fig. 4 and Supplementary Table 2). These data were consistent 
with the observation that glia cells in the AD brain did not accumulate detectable levels of 
pathological tau (Supplementary Fig. 2).
BAG3 is a hub gene in the co-expression network relevant to tau homeostasis
In order to identify a key master regulator responsible for modulating tau aggregates among 
the subproteomes linked to tau homeostasis we performed a co-expression network 
analysis27 on the SNS dataset. This type of analysis quantifies the covariation of genes 
within given samples or brain regions (cell types in our case), by measuring a quantity of 
reference, like the Pearson’s correlation coefficient. In this network, each gene is represented 
by a node and the co-expression values correspond to the weights associated with each link 
connecting two nodes. Although more complex approaches are possible27, a direct way to 
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identify the hub genes that are central in the network is to sum the weights of all the links 
connected to a gene which is defined as the total degree of a node. When the top 10% of the 
genes in the higher degree were isolated (highlighted with the labels in Figure 5), the only 
gene belonging to both the protector subproteome and to the top 10% of the most co-
expressed genes was BAG3. All the rest of the genes belonged either to the metastable 
subproteome or to the tangles, and no genes belonging to the promoter group was found 
among the hub genes (see Supplementary Table 3).
Validation of the localization and expression levels of representative tau homeostasis 
signature genes by single-molecule FISH in human EC and prefrontal cortex
We next validated the results of the single-nucleus RNA-seq analysis of several AD-related 
genes including MAPK1 (tau co-aggregators), FKBP5 (tau aggregation promoter), ENC1 
(MS) and MAPT (the gene encoding tau) using the single-molecule RNA FISH assay. The 
mRNA levels of MAPK1, FKBP5 and ENC1 were significantly higher in EX neurons than 
in IN neurons in both EC and BA9 while there was no significant difference in the mRNA 
levels corresponding to MAPT (Fig. 6). These results support the conclusion that in 
vulnerable regions, EX neurons exhibit a cellular environment more conducive to tau 
aggregation and susceptibility to tau homeostasis dysfunction than IN neurons.
Validation of BAG3 protein levels in IN neurons and EX neurons of unaffected and AD brain 
tissue.
To validate whether the protein level of one of the genes identified by the RNA analysis was 
differentially regulated between IN and EX neurons, and whether this was seen in both 
unaffected (non-AD) and AD brain we examined the levels of BAG3 by 
immunofluorescence staining in the BA9 region of post-mortem human tissue. The level of 
BAG3 in NeuN+ neurons that labelled with the IN cell marker GAD1 (GAD1+/NeuN+) was 
significantly higher in both non-AD and in AD neurons than in NeuN+ neurons that were 
negative for GAD1 (GAD1-/NeuN+ cells (P < 0.001, Supplementary Fig. 7). These cells 
were presumed to be mostly EX as the great majority of NeuN+/GAD1- neurons co-label 
with EX neuron markers (data not shown). Of note, the level of BAG3 protein was much 
higher in non-neuronal cells (NeuN- cells) than in neurons (NeuN+ cells) (Supplementary 
Fig. 7a). These results are consistent with our findings of almost no accumulation of 
pathological tau in IN neurons and glial cells.
Modulating the expression of BAG3 affects tau accumulation in primary cortical neurons
In order to further validate our results and confirm that genes identified through the 
bioinformatics analysis can contribute to the vulnerability of neurons to tauopathy, we 
manipulated the mRNA levels of BAG3, a master regulator gene and one of the major tau 
aggregation protectors associated with tau homeostasis21 that was enriched in inhibitory 
neurons (Supplementary Table 1). BAG3 was of particular interest as it interacts with the co-
chaperone HSPB8, which was also more highly expressed in IN neurons than in EX neurons 
(Supplementary Table 1). We found that knockdown of BAG3 using shRNA lentivirus in 
primary neurons from wild-type mice (Fig. 7a and Supplementary Fig. 11) induced the 
accumulation of endogenous tau recognized by the 12E8 antibody, mainly in neurites (Figs. 
7b and 7c, P < 0.01). In primary neurons expressing tau RD-P301S-YFP (an FTLD causing 
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mutation), knockdown of BAG3 led to an accumulation of tau in both cell bodies and 
neurites (Figs. 7d-f, P < 0.01). Overexpression of BAG3 significantly attenuated tau 
accumulation in EX neurons (Figs. 7d and 7e, P < 0.01). There was a trend towards 
decreased tau accumulation in IN neurons where BAG3 was overexpressed but the data did 
not reach significance (Fig. 7f, P = 0.098) most likely due to the very low level of tau 
aggregates in IN neurons in general. These results support our conclusion that genes 
associated with tau protein homeostasis contribute to neuronal vulnerability to tau pathology.
Discussion
Understanding the molecular origins of selective cellular vulnerability is of fundamental 
importance for all of the neurodegenerative diseases28. Unfortunately, the molecular 
determinants of selective vulnerability have so far remained unclear, in part because we lack 
sufficient information on the molecular makeup of subpopulations of cells that are 
compromised in a particular brain region, by a particular protein, and in a particular disease. 
In this study, we addressed this problem with regard to tau using a mouse model of 
tauopathy, as well as human AD brains at different Braak stages. The EC-tau mouse 
model20, 29 demonstrates progressive tauopathy that originates in the hippocampal formation 
but spreads to extrahippocampal and neocortical areas with age30. Because the model shows 
spread of the pathology we can dissociate primary vulnerability from secondary 
vulnerability that occurs as a result of non-cell autonomous tauopathy propagation. Primary 
vulnerability is seen in neurons of the MEC that develop tau pathology early, whereas 
secondary vulnerability is seen in neurons of the PRH and NC which develop pathology 
much later. We demonstrated that tau aggregates predominantly accumulate in EX neurons 
compared to IN neurons, not only in the primary affected region but also in secondary 
regions suggesting that EX neurons are vulnerable to both cell autonomous and non-cell 
autonomous accumulation of tau as tauopathy propagates.
Previous studies have explored why putative EX neurons could be particularly vulnerable to 
degeneration in AD and other neurodegenerative disorders6, 13–15. However, mechanisms 
underlying selective vulnerability of EX neurons to tau pathology have not been identified 
and tested. Our approach to answering this question was prompted by recent observations 
that age-related stress and dysfunction of protein homeostasis are observable in vulnerable 
neurons in aging and age-related neurodegenerative diseases14, 16–18. In particular, a 
transcriptional analysis of healthy brains at ages well before the typical onset of AD 
identified a protein homeostasis signature associated with protein aggregation, and predicted 
the Braak staging of AD19. The protein homeostasis signature included a set of aggregation-
prone proteins (metastable subproteome)26 and three other sets of protein homeostasis 
components (co-aggregators, aggregation promoters, and aggregation protectors)18. The 
overall relative expression of the protein homeostasis signature was elevated significantly in 
neurons compared with other cell types indicating that neurons have a cellular environment 
most conducive to protein aggregation compared to other brain cell types19.
Based on these results, we hypothesized that an intrinsic difference in the tau homeostasis 
system could contribute to the selective vulnerability of EX neurons to tau pathology. After 
analyzing two independent single-nucleus RNA-seq datasets from healthy donors we 
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showed that EX neurons are characterized by elevated expression of a specific subset of 
aggregation-prone proteins (the metastable subproteome) and tau aggregation promoters, as 
well as by the decreased expression of tau aggregation protectors. These findings suggest 
that the selective vulnerability of EX neurons to tau aggregation, particularly in regions of 
the brain that are affected early on in AD, could be due to the intrinsic susceptibility of EX 
neurons to dysregulation of the branch of the protein homeostasis system that regulates tau 
aggregation. Since there are currently only two single-nuclei RNA-seq datasets from post-
mortem human brain tissue publically available and they do not contain the exact same 
regions of the brain, we could not compare region-matched datasets. However, we still found 
that tau homeostasis gene signatures differed between EX and IN neurons in early and late 
affected region, even though the regions considered were not the same.
In support of this idea is the finding of relatively high expression of tau aggregation 
protectors in IN neurons and other cell types such as microglia that are resistant to 
pathological tau accumulation, in agreement with previous findings19. Differential regulation 
of several of the genes were validated at the mRNA level, and the protein level of one, 
BAG3, a master regulator belonging both to the “protectors” subproteome and to the top 
10% of most co-expressed genes, was shown to be significantly higher in IN neurons than in 
putative EX (NeuN+/GAD1-) neurons in both non-AD and AD cases supporting our finding 
that tau does not accumulate in IN neurons in AD brain. Furthermore, when we attenuated 
the level of BAG3 in primary neurons, the vulnerability of the cells to accumulate tau was 
significantly enhanced. As the promoter used to drive expression of the BAG3 shRNA or 
cDNA is not specific for neuron types, BAG3 mRNA was modulated in both EX and IN 
neurons. We expected the levels of tau to be attenuated in both EX and IN neurons in 
response as our RNA data had shown that the gene is differentially, not selectively regulated 
between the two neuron types, but it was noteworthy to observe that when BAG3 expression 
was reduced, tau accumulated in GAD+ IN neurons. We have only observed tau 
accumulating in IN neurons very rarely in the mouse or human studies. Conversely, 
vulnerability was reduced in neurons when BAG3 was overexpressed. This data confirms 
that the gene is impactful in IN neurons.
Our results indicate that neurons (and EX neurons in particular) represent a cellular 
environment more vulnerable to pathological tau accumulation compared to glial cell types 
which is consistent with the finding that tau does not accumulate appreciably in glia in the 
AD brain. However, tau has been shown to accumulate in glia (tufted astrocytes and 
oligodendrocytes) in some, but not all of the primary tauopathies31–33. Why tau should 
accumulate in glia in some tauopathies is not known but it likely results from a combination 
of different forms of tau in different tauopathies, and the sets of homeostasis genes in each 
cell type that control their likelihood to accumulate.
Our results are consistent with the known effects of impaired protein homeostasis on 
pathogenesis in age-related neurodegenerative diseases14, 16–18. Our findings characterize a 
subset of proteins that are highly specific for tau homeostasis and they complement previous 
studies on protein subnetworks responsible for protein homeostasis in different 
neurodegenerative disorders34. We anticipate that further demonstrations of the complex and 
highly regulated interactions between different protein homeostasis components will reveal 
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more determinants of the vulnerability of specific neuron types. Lastly, our findings 
emphasize the importance of pursuing novel therapeutic strategies of enhancing natural 
defense mechanisms that maintain our proteome in a soluble state35, 36, and the use of 
protein homeostasis enhancing therapeutics, especially if they can be designed to target 
specific cell types, such as vulnerable EX neurons.
ONLINE METHODS
Reagents.
Human conformation-dependent tau (MC1) and human/murine phospho-tau pSer396/ 
Ser404 (PHF1) monoclonal antibodies were provided by Dr. Peter Davies. Mouse anti-
phosphorylated tau Ser262 and/or Ser356 (12E8) antibody37 is a kind gift from Dr. Philip 
Dolan. Human/murine phospho-tau pSer202/Thr205 (AT8, Cat# MN1020) and pThr212/
Ser214 (AT100, Cat# MN1060) monoclonal antibodies, rabbit anti-phospho-tau pSer422 
(pS422, Cat# 44–764G) and parvalbumin (PVALB, Cat# PA5–18389) polyclonal antibodies, 
Alexa Fluor dye-labeled cross-absorbed goat and donkey secondary antibodies (Cat# 
A-11029, A-11037, A-11007, A-11058, and A-21202), SlowFade gold (Cat# S36937) and 
ProLong gold (Cat# P36934) antifade reagents were purchased from Thermo Fisher 
Scientific. Rabbit anti-TBR1 (Cat# ab31940) and SATB2 (Cat# ab92446) polyclonal 
antibodies were purchased from Abcam. Rat anti-somatostatin (SST) (Cat# MAB354) and 
mouse anti-NeuN (Cat# MAB377) monoclonal antibody and goat anti-GAD1 (Cat# 
AF2086) polyclonal antibody were purchased from Millipore and R&D Systems, 
respectively. Rabbit anti-calretinin (CALB2) (Cat# 7697), IBA-1 (Cat# 019–19741), and 
GFAP (Cat# G9269) polyclonal antibodies were purchased from Swant, Wako and Sigma-
Aldrich, respectively. RNAscope Multiplex Fluorescence Kit (Cat #320851) and human 
specific RNA probes including SLC17A7 (Cat# 415611 or 415611-C2), GAD1 (Cat# 
404031-C3), MAPT (Cat# 472621), MAPK1 (Cat# 470741), FKBP5 (Cat# 481101) and 
ENC1 (custom probe) were purchased from Advanced Cell Diagnostics. TrueBlack 
lipofuscin autofluorescence quencher (Cat# 23007) was purchased from Biotium. Lentiviral 
vectors FG12-scramble and FG12-shBAG3 were prepared as previously described21, and the 
GFP in these vectors was removed by cutting with AgeI and BsrGI followed by fill-in of 5’ 
overhangs and re-ligation. The shRNA-resistant BAG3 in FigB was made by changing the 
underlined bases of the shRNA target sequence (AAG GTT CAG ACC ATC TTG GAA) 
which does not change the amino acid but results in an shRNA resistant BAG3 (AAA GTA 
CAA ACT ATC TTG GAA). Viral packaging vectors psPAX2 and VSVG are kind gifts 
from Dr. Christoph Pröschel. Tau RD-P301S-YFP (aa 244–372 of the 441 amino acids in 
full-length tau; mutations P301S) and the clone 9 (DS9) tau seeds (gifts of Dr. Marc 
Diamond) were prepared as previously described38. Rabbit anti-TBR1 (Cat# 20932–1-AP) 
and rabbit anti-BAG3 (Cat# 10599–1-AP) polyclonal antibody were purchased from 
Proteintech Group. Unless otherwise noted, all other reagents were purchased from Fisher 
Scientific or Thermo Fisher Scientific.
Animals.
We previously generated a tau transgenic mouse model known as EC-tau20 by crossing the 
neuropsin-tTA activator line with a tetracycline-inducible tau P301L responder line. The F1 
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offspring (both males and females at 22 and 30+ months old, strain FVB/N:C57BL/6) were 
used as experimental animals. All animals were maintained on a 12 hr light/dark cycle with 
food and water provided ad libitum. All animal experiments were performed in accordance 
with national guidelines (National Institutes of Health) and approved by the Institutional 
Animal Care and Use Committee of Columbia University (IACUC protocol # AC-
AAAN9950). Mice were transcardially perfused with phosphate-buffered saline (PBS), 
brains were harvested and drop-fixed in 4% paraformaldehyde (PFA) (Cat# 15710, Electron 
Microscopy Sciences) in PBS at 4 °C overnight, and free-floating sections (35 μm) were 
prepared as previously described39.
Human brain tissues.
Human free-floating sections (40 μm) and formalin-fixed paraffin-embedded (FFPE) 
sections (10 μm) were provided by the Brain Bank at Banner Sun Health Research Institute. 
Human fresh frozen brain blocks were provided by the New York Brain Bank at Columbia 
University Medical Center and the NIH NeuroBrainBank at the University of Maryland 
Brain and Tissue Bank. The demographics of human cases used in this study are listed in 
Supplementary Table 4. These specimens were obtained by consent at autopsy and have 
been de-identified and are IRB exempt so as to protect the identity of each patient. Frozen 
sections (10 μm) were cut from frozen blocks under RNase-free conditions by the Histology 
Service at Columbia University Medical Center.
Immunofluorescence staining on mouse and human brain sections.
Immunostaining was performed as previously described with a few modifications for human 
brain sections39. Free-floating brain sections from EC-tau and age-matched nontransgenic 
(WT) mice at 22 and 30+ months as well as from human brains were subjected to antigen 
retrieval by 10-minute incubation in 10 mM sodium citrate (pH6.0, 95 °C). After blocking, 
the sections were stained with TBR1 (1:250), SATB2 (1:250), PVALB (1:1,000), SST 
(1:100) or CALB2 (1:1,000) antibodies in the blocking solution on the first day, followed by 
incubation with MC1 (1:750), AT8 (1:500), PHF1 (1:500) or pS422 (1:250) tau antibodies 
on the next day. Fresh frozen human brain sections were air-dried and fixed with cold 
acetone for 10 min at −20 °C. They were then incubated with TBR1 (1:250), SATB2 
(1:250), GAD1 (1:100) or GFAP (1:2,500) antibodies in blocking solution, followed by 
incubation with AT8 (1:500), PHF1 (1:500), pS422 (1:250) or AT100 (1:500) tau antibodies 
on the next day. Human FFPE sections were deparaffinized and rehydrated before the same 
procedure of antigen retrieval described above, followed by sequential immuno-labeling 
with TBR1 (1:250), SATB2 (1:250) or IBA-1 (1:500) antibodies and MC1 or AT8 tau 
antibodies (1:500). We chose the sequential staining instead of the more common co-
staining because we found significant amounts of co-localization artifacts of tau and 
neuronal markers, especially SST. After three washes with phosphate buffered saline with 
Tween 20 solution (PBST), the sections were incubated with appropriate Alexa Fluor dye-
labeled cross-absorbed goat or donkey secondary antibodies (1:1000) for 2 hr (mouse 
sections) or 3 hr (human sections) at room temperature. Following three washes with 
phosphate buffered saline solution (PBS), autofluorescence was quenched with 0.3% Sudan 
black in 70% ethanol for 6 min (mouse sections) or 12 min (human sections) at room 
temperature. The nuclei were stained with 5 mg/ml Hoechst33342 (Cat# 14533, Sigma-
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Aldrich) in PBST for 10 min at room temperature. Following three washes with PBS, 
sections were mounted on slides using SlowFade gold antifade reagent and imaged using 
confocal laser scanning microscopy (LSM800, Zeiss) via z-stack to assess co-localization. A 
fluorescence microscope (BX51, Olympus) was used for quantitation. The number of 
neuronal marker+, MC1+, and co-stained neurons in layers II-IV of the MEC, PRH, and NC 
was quantified manually using ImageJ software.
The co-staining of GAD1 (1:100), NeuN (1:250) and BAG3 (1:100) was performed on 
human brain frozen sections (BA9 region) as described above. Stained sections were imaged 
using confocal laser scanning microscopy via z-stack. We used ImageJ software to open the 
original czi files, customize the channel colors, set measurements in analysis (mean intensity 
and area), select different types of neurons by drawing a circle around the cell. The 
“measure” function generated the analysis. The automatically generated values for similar-
sized EX (GAD1-/NeuN+) and IN (GAD1+/NeuN+) neurons were used for comparison of 
the protein levels of BAG3.
Single-nucleus RNA-seq data analysis.
We used two single-nucleus RNA-seq annotated datasets, the SNS (http://genome-
tech.ucsd.edu/public/Lake_Science_2016/)24 and the DroNc-Seq dataset (https://
portals.broadinstitute.org/single_cell)25. A differential expression analysis was performed 
on both datasets. Raw data were first log-normalized, and then a z-score normalization was 
performed for all genes across the samples to enable a direct comparison between them. 
Genes with replicates were first z-scored and then the averaged across different samples. In 
the case of the DroNc-Seq dataset, the matrix of transcript reads had many zero entries 
within the transcriptome. In order to avoid biases in the analysis and reduce the amount of 
noise, the bottom 5% low quality samples (samples with less reads across the transcriptome) 
were discarded, as they were considered to have been damaged during the experimental 
procedure. A Δ score19 for the genes corresponding to each subproteome was calculated as 
Δ s = E s , i −   E s , j  , which represents the difference between the average 
expression value (E) computed, taking the subproteome {s} of reference, in the cell types {i} 
(e.g. excitatory (EX) neurons), and {j} (e.g. inhibitory (IN) neurons) respectively. Cells were 
classified as either EX or IN neurons, or non-neuronal based on canonical marker gene 
expression. More specifically, cells were classified as EX neurons if the maximum 
expression of EX genes (SLC17A6, SLC17A7) was greater than the maximum expression of 
IN (GAD1, GAD1, SLC32A1) or non-neuronal (OLIG1, GJA1, XDH, CTSS, MY19) genes. 
Cells were classified as IN neurons if the maximum expression of IN ( GAD1, GAD1, 
SLC32A1) genes was greater than the maximum expression of EX ( SLC17A6, SLC17A7) 
or non-neuronal (OLIG1, GJA1, XDH, CTSS, MY19) genes. All remaining cells were 
classified as non-neuronal40. For the SNS dataset, we combined brain regions BA21, 22, 10, 
and 41, and considered them to be a region affected early in AD (low Braak stage). BA17 
was considered to be a region affected later in AD (higher Braak stage) region. For the 
DroNc-Seq dataset, hippocampus (HP) was considered to be an early affected region, while 
the prefrontal cortex (PFC/BA9) was considered to be a later affected region4.
Fu et al. Page 10
Nat Neurosci. Author manuscript; available in PMC 2019 June 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statistical analysis of the RNA-seq results.
The statistical significance of the results in Figs. 3 and 4 is studied by creating a null model 
for each subproteome under scrutiny. This approach enables the assessment of the statistical 
significance of a given result, and consists of the comparison between a specific value and a 
distribution of values obtained from multiple random samples of the same size as the 
reference sample. Each delta-score Δ s  associated with a subproteome {s} containing ns 
genes, obtained as a global average of the expression values of the group of genes of interest, 
is directly compared to a distribution of delta-scores, obtained by sampling multiple times 
the transcriptome of reference and by creating multiple random subproteomes of the same 
size ns as the reference one. The p-value is then the probability of obtaining a value which is 
more extreme than the empirical one, using the random distribution as a reference.
Weighted gene co-expression network analysis.
Weighted gene co-expression network analysis is a data mining method that allows the 
quantification and interpretation of correlations between variables. In biology, this approach 
is widely used to study the covariation of genes and proteins across different samples and 
conditions (different cell types in our analysis). It is based on the definition of a similarity 
measure, the Pearson’s correlation coefficient in our case, which serves as a parameter to 
build the topology of the network. The Pearson’s correlation coefficient is defined as
ρX, Y =
cov X, Y
σXσY
where cov X, Y = E X − μX Y − μY  is the covariance among genes X and Y across the cell 
types (with μX and μY being the mean values of X and Y, respectively), and σX and σY are 
their standard deviations. In order to quantify the centrality of each gene in the network, 
different measures are possible. We selected the total degree of a node, which is defined as 
the weighted sum of the links connecting it to all the other nodes in the network, with each 
link being weighted by the Pearson’s correlation coefficient computed above.
Single-molecule fluorescent in situ hybridization (smFISH).
Fresh frozen sections from healthy adults were fixed while frozen in 4% PFA and stained 
with human specific RNA probes (MAPT/MAPK1/FKBP5-C1, SLC17A7-C2 and GAD1-
C3; SLC17A7-C1, ENC1-C2 and GAD1-C3) using the RNAscope Multiplex Fluorescence 
Kit according to manufacturer’s instructions. After staining, background lipofuscin 
autofluorescence was quenched using 1% True black (Biotium). Following nucleus 
counterstaining with DAPI, sections were mounted with ProLong gold antifade reagent. 
Stained sections were imaged by confocal laser scanning microscopy (LSM800, Zeiss) with 
a 63x objective. Images were taken across the superficial layers of the EC or BA9 to ensure 
reproducibility, totaling 10 images per section. Single-mRNA signals from 40 EX and 40 IN 
neurons (10 neurons from each human case, 4 cases in total) were manually quantified using 
the ZEN 2 (blue edition, Zeiss), and the results were expressed as the percentage of the 
average count of single-mRNAs in IN neurons. Data was analyzed and graphed using Prism 
5 software (GraphPad).
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Mouse primary cortical neuron culture and viral transduction.
Primary mouse neurons were prepared from embryonic day 16–18 mouse embryos and 
cultured as described with some modifications41. All procedures were approved and 
performed in compliance with the University of Rochester guidelines for the care and use of 
laboratory animals. In brief, cerebral cortices were isolated from the mouse brains, meninges 
were removed, then the cortices were transferred into Trypsin-EDTA (0.05%) and digested 
for 15 minutes. Following gently trituration, neurons were plated at a density of 15,000 
cells/cm2 on poly-D-lysine-coated (Sigma) coverslips for imaging. Neurons were grown for 
day in vitro (DIV) 24–26 in maintenance media (Neurobasal-A medium supplemented with 
2% B27 and 2 mM GlutaMax), and half of media was replaced every 3–4 days. For lentiviral 
transduction, DIV14 neurons were treated with scrambled or shBAG3 without GFP virus in 
a half volume of growth media for 16 hours, then the conditioned media supplemented with 
an equal volume of fresh media was added back.
Immunofluorescence staining of endogenous tau accumulation in primary neurons.
Eleven days after transduction with scrambled or shBAG3 virus the neurons were rinsed 
with PBS twice, followed by fixing in PBS containing 4% paraformaldehyde and 4% 
sucrose for 5 minutes at room temperature. Cells were then permeabilized in PBS containing 
0.25% Triton X-100 for 10 minutes at room temperature, and were blocked with PBS 
containing 5% BSA and 0.3 M glycine. Primary antibodies were diluted in blocking solution 
as follows: goat anti-GAD, 1:1000; rabbit anti-TBR1, 1:500; mouse anti-12E8, 1:2000, 
incubated on a shaker at 4°C overnight. The next day, neurons were washed with PBS 3 
times, 10 minutes each time. Alexa Fluor 488 conjugated donkey anti-rabbit IgG (1:1000), 
Alexa Fluor 594 conjugated donkey anti-mouse IgG (1:1000) or Alexa Fluor 647 conjugated 
donkey anti-goat IgG (1:1000) was diluted in blocking solution and incubated with neurons 
for 1 hour at room temperature. After 3 × 10 minutes of washes, neurons were incubated 
with Hoechst 33342 (2μM) for 10 minutes at room temperature, then coverslips were 
mounted with ProLong diamond antifade mountant. Images were acquired on the laser 
scanning confocal microscope (LSM800, Zeiss) via z-stack. The maximum z projection of 
those images was used for looking at the tau puncta in the neurites.
Western blot analysis.
Primary cortical neurons cultured in 6-well plates were transduced with scramble, shBAG3 
or BAG3 OE lentivirus for 7 days and the total protein lysates were prepared and subjected 
to Western blot assay as previously described42. 2.5 μg of protein lysates were separated 
electrophoretically on 4–12% Bis-Tris precast polyacrylamide gels and blotted onto 
nitrocellulose blotting membranes. Blots were probed with rabbit primary antibodies for 
BAG3 (1:5000) or GAPDH (1:6000). After washing and incubation with secondary 
horseradish peroxidase-conjugated antibodies, membranes were developed with ECL, and 
digitalized images were taken using Fujifilm LAS-3000 Imager.
Neuronal culture, viral transduction and tau seeding experiment.
Primary neuronal cultures were prepared and maintained as previously described43. At 
DIV2, neurons cultured on poly-D-lysine-coated coverslips were transduced with the 
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scramble, shBAG3 or BAG3 OE lentivirus. Half of the media was changed and neurons were 
transduced with 2 μl of RD-P301S-YFP (1:100) lentivirus. At DIV5, the media was changed 
and cells were incubated with 7.5 μg of DS9 tau seeds (prepared in sterile PBS) overnight. 
The media was then changed into the growth media and incubated for an additional 4–6 
days. The cells were fixed with 4% PFA at room temperature for 30 min and were subjected 
to immunofluorescent staining as described above. Cells were incubated with the primary 
antibodies of rabbit anti-TBR1 (1:750) and goat anti-GAD1 (1:750) at 4 °C overnight, 
followed by the incubation of appropriate secondary donkey antibodies at room temperature 
for 2 h. Images were acquired on the laser scanning confocal microscope (LSM800, Zeiss) 
at 20× magnification, the whole view of which was used as the region of interest (ROI). 
Each group has 4 coverslips, and 20 images per coverslip at 1,024 × 1,024 resolution were 
taken randomly from all the orientations of the coverslip. The number of TBR1+ EX and 
GAD1+ IN neurons with tau inclusions were quantified blind to the treatment.
Statistical analysis.
No statistical methods were used to pre-determine sample sizes but our sample sizes are 
similar to those reported in previous publications38, 39, 43. Prism 5 software was used to 
analyze the data. All the data are expressed as mean ± SEM. We performed the D’Agostino-
Pearson omnibus normality test to determine if the data were normally distributed, or the F 
test to determine if the data assumed equal variances. We then chose the following statistical 
tests. The unpaired t test was used to compare the number of neuronal marker+ and MC1+ 
cells in EC-tau and control mice. A one-way ANOVA with Tukey’s post-tests was used to 
compare the number of neuronal marker+ cells in human brains at different Braak stages. 
The unpaired t test with Welch’s correction was used to compare the number of MC1+ cells 
in human brains, and the number of single-mRNAs between EX and IN neurons. The 
nonparametric Mann-Whitney test was used to compare the mean intensity of BAG3 in 
human non-AD and AD. The nonparametric Kruskal-Wallis test with the post hoc test of 
Dunn’s multiple comparisons was used to compare the ratio of colocalization, the number of 
neurons with 12E8 tau+ puncta, the number of TBR1+ neurons with tau inclusions, and the 
number of GAD1+ neurons with tau inclusions. All results represent two-sided tests 
comparing groups of biological replicates. A value of p < 0.05 was considered statistically 
significant for all measures. The “n” represents the number of animals, neurons, or cases in 
each group. The exact values of n are indicated in figure legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Excitatory and inhibitory neurons are differentially vulnerable to tau pathology in 
primary and secondary affected regions of EC-tau mice.
(a, b) Representative images of MC1-positive (+) tau staining co-localized with TBR1+ and 
SATB2+ excitatory (EX) neurons, but not PVALB+, SST+ or CALB2+ inhibitory (IN) 
neurons, in the MEC of EC-tau mice at 22 months (a) and at 30+ months (b). Three 
independent experiments were repeated with similar results. Scale bar, 20 μm. c) Co-
localization ratio of MC1+ tau with neuronal marker+ neurons, which was quantified in the 
MEC, PRH and NC (layers II-IV) of EC-tau mice at 22 and 30+ months. (d, e) Number of 
neuronal marker+ neurons (d) and MC1+ cells (e), which was counted in the above regions 
of EC-tau mice at 22 and 30+ months. (f) Number of TBR1+ and SATB2+ EX neurons, 
which was compared in the MEC of non-transgenic (WT) mice at 22 and 30+ months. Data 
are presented as mean ± SEM (n = 6 animals, 2 sections each animal. If the section does not 
have any MC1+ neurons, it will be removed out of the analysis, e.g. PRH-22 mo: n = 9; 
PRH-30+ mo: n = 11; NC-22 mo: n = 6; NC-30+ mo: n = 11 independent sections) (c, d, f) 
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and (n = 7 independent experiments, each value is the average of 12 biological independent 
sections) (e). Statistical significance was assessed by Kruskal-Wallis test with the Dunn’s 
multiple comparison test (c) and one-way ANOVA with Tukey’s post-test (d). *** P < 
0.0001 vs PVALB, SST and CALB2 (the same brain regions and ages of the mice) (The 
Kruskal-Wallis statistic is 53.16, 53.09, 41.17, 49.65, 29.37 and 48.02, respectively.) (c); *** 
P < 0.0001 vs 30+ months (the same brain regions and neuronal markers) (The R squared = 
0.6996, F = 34.16) (d). In (e, f), statistical significance was assessed by two-tailed unpaired t 
test. NS, not significant; *** P < 0.0001 vs 22 months (The statistic is t=6.921, df=12; 
t=8.833, df=12; t=16.56, df=12 (e); t=0.2748, df=22; t=0.2040, df=22 (d), respectively.).
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Figure 2. EX and IN human neurons are differentially vulnerable to tau pathology in primary 
affected regions of AD brain.
(a, b) Representative images of MC1-positive (+) tau staining co-localized with TBR1+ and 
SATB2+ EX neurons, but not PVALB+, SST+ or CALB2+ IN neurons, in the EC of AD 
patient brain at Braak stage II (a) and Braak stage V-VI (b). Three independent experiments 
were repeated with similar results. Scale bar, 20 μm. (c) Co-localization ratio of MC1+ tau 
with neuronal marker+ neurons, which was quantified in the EC layer II-IV of AD brains at 
different Braak stages; data are presented as mean ± SEM (n = 3 cases, 2 sections each 
case), and the statistical significance was assessed by Kruskal-Wallis test with the Dunn’s 
multiple comparison test. *** P < 0.0001 vs PVALB, SST and CALB2 (the same Braak 
stage) (The Kruskal-Wallis statistic is 9.280, 25.82 and 24.90, respectively.). (d, e) Number 
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of neuronal marker+ neurons (d) and MC1+ cells (e), which were assessed in EC layer II-IV 
of AD brains at different Braak stages; data are shown as the percentage of the average 
number of neuronal marker+ cells at Braak stage I-II and are presented as mean ± SEM (n = 
3 cases, 2 sections each case), and the statistical significance was assessed by one-way 
ANOVA with Tukey’s multiple comparison post hoc tests (The R squared = 0.6026, F = 
11.37; R squared = 0.5187, F = 8.082) (d) or two-tailed Unpaired t test with Welch’s 
correction (e). ** P < 0.01; *** P < 0.001 vs Braak stage I-II (The statistic is t=6.369, df=6; 
t=4.150 df=6).
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Figure 3. Single-nucleus RNA-seq analysis reveals a specific tau homeostasis signature in EX 
neurons in human brains.
(a, b) Comparison of the differential expression of relevant subproteomes for different cell 
types. For each subproteome (and the whole transcriptome as a control), the difference 
between the mean expression in EX and IN neurons (measured by the Δ score, see Methods) 
was calculated, and the values are presented as mean ± SEM. In (a, b) results are reported 
for the SNS and the DroNc-Seq datasets, respectively. (c, d) Comparison of Δ scores for five 
subproteomes (and the whole transcriptome as a control) within the EX neurons, between 
regions affected relatively early or late in AD for the SNS and DroNc-Seq datasets, 
respectively. The significance was evaluated by building a null model for each subproteome 
(see Methods, Supplementary Table 1 and Supplementary Figures 4–6) and corrected with a 
Benjamini-Hochberg multiple hypothesis testing correction *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Subproteomes (where nsns and ndrnc are the sample sizes corresponding to 
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SNS and DroNc-seq datasets respectively): EX markers (excitatory markers, a set of genes 
specific for excitatory neurons): nsns=ndrnc=2; promoters (a set of proteins promoting tau 
aggregation): nsns=ndrnc=6; MS (metastable subproteome, a subset of highly expressed and 
aggregation-prone proteins, which are supersaturated – i.e. proteins whose concentration in 
the cellular environment is higher than a critical value keeping them soluble and functional – 
and downregulated in AD): nsns=162, ndrnc=179; transcriptome (the whole transcriptome, 
here reported as a negative control); tangles (proteins co-aggregating with tau and found in 
neurofibrillary tangles): nsns=57, ndrnc=68; protectors (a set of proteins protecting tau from 
aggregating): nsns=ndrnc=6; IN markers (inhibitory markers, a set of genes specific for 
inhibitory neurons): nsns=ndrnc=3.
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Figure 4. Single-nucleus RNA-seq analysis shows high levels of tau aggregation protectors in glia.
Differential expression of relevant subproteomes for different cell types. For each 
subproteome (and the transcriptome of reference as a control) the difference between the 
mean expression in glia and neurons (measured by the Δ score, see Methods), within cell-
types from different regions was calculated. In (a, b, c) differential expression values 
between glia and EX neurons are reported. Specifically, results are reported for (a) microglia 
(MG), (b) astrocytes (ASC1, ASC2), and (c) oligodendrocytes (ODC1, ODC2), respectively. 
(d, e, f) Differential expression between glia and IN neurons are reported, with values 
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corresponding to (d) microglia (MG), (e) astrocytes (ASC1, ASC2), and (f) 
oligodendrocytes (ODC1, ODC2), respectively. For each bar, the significance was evaluated 
by building a null model for each subproteome and corrected with a Benjamini-Hochberg 
multiple hypothesis testing correction *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (see 
Methods, Supplementary Table 2 and Supplementary Figures 8–10). Results are reported for 
the DroNc-Seq dataset. Subproteomes: tau (MAPT gene); the definition of promoters, 
transcriptome, tangles, and protectors, and the sample sizes are the same as Figure 3.
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Figure 5. Co-expression network analysis of the subproteomes relevant to tau homeostasis.
Sketch of the co-expression network to identify hub genes of the subproteomes related to tau 
homeostasis. The network is fully connected, and the edges linking the genes (nodes) are 
weighted with the Pearson’s correlation coefficient. The hubs, which are defined as the 
genes more tightly co-expressed with every other gene in the network, and here defined as 
master regulators, are highlighted with the labels (top 10% of the most co-expressed genes). 
The size of each node is proportional to the sum of the weights of the edges connected to it. 
BAG3 is a hub in the protectors region of the network (lower left). The color code identifies 
the different subproteomes: MS (red), tangles (green), protectors (blue), promoters (yellow), 
tau (black), and with the genes shared between MS and tangles colored in brown.
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Figure 6. Validation by single-molecule FISH of the localization and mRNA expression levels of 
representative tau homeostasis signature genes in human EC and prefrontal cortex.
(a, b) Representative sm-FISH images of the co-staining of EX neuronal marker (SLC17A7, 
red), IN neuronal marker (GAD1, purple), and target probe (MAPT, MAPK1, FKBP5 and 
ENC1, green) in the EC (a) and the BA9 (b) of human brain without pathological hallmarks 
of neurodegenerative diseases (54–66 years old); dotted ovals represent individual EX or IN 
neurons. Three independent experiments were repeated with similar results. Scale bar, 10 
μm. (c, d) Comparison of the number of single RNAs of the target probe in individual EX 
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and IN neuron in the EC (c) and the BA9 (d) regions (n = 4 human brains, 10 neurons from 
each case). Data are presented as mean ± SEM. The statistical significance was assessed by 
two-tailed unpaired t test with Welch’s correction. *** P < 0.0001 vs IN neurons (The 
statistic is t=8.061, df=47; t=6.181 df=42; t=10.77, df=39 (c); and t=7.981, df=48; t=4.675, 
df=56; t=12.60, df=41 (d), respectively.).
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Figure 7. Modulating the expression of one of the tau aggregation protectors, BAG3, affects tau 
accumulation in primary cortical neurons.
(a) Representative western blot images of primary cortical neurons transduced with 
lentivirus expressing scrambled BAG3 or shBAG3, or overexpressing BAG3 (OE) as 
described in Online Methods. GAPDH is a housekeeping protein used as the loading control. 
Three independent experiments were repeated with similar results. Full length of the blot 
can be found in the Supplementary Fig. 11. (b) The percentage of EX and IN neurons (n = 
55 from 11 coverslips each group) with 12E8 (pS262 and/or pS356 tau)-positive (+) puncta 
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(≥ 5) in the neurites was quantified as described in Online Methods. (c) Representative 
immunocytochemical images of 12E8+ (red) puncta (white arrow heads) in the neurites of 
TBR1+ (green) EX neurons. White arrow indicates a neuron with high expression of TBR1; 
yellow arrow indicates a neuron with low expression of TBR1. GAD1+ (purple) IN neurons 
were also transduced with shBAG3 lentivirus and tau was shown to accumulate in neurites 
(white arrowheads). Three independent experiments were repeated with similar results. (d) 
Representative immunocytochemical images of tau inclusions (green) in TBR1+ (red) EX 
neurons (white dotted circle) (white arrow, high expression of TBR1; yellow arrow, low 
expression of TBR1) and tau inclusions (green) in GAD1+ (purple) IN neurons (yellow 
dotted circle) transduced with different lentiviruses as described in Online Methods. The 
nuclei were counterstained with Hoechst33342 (blue). Three independent experiments were 
repeated with similar results. Scale bars, 50 μm (c); 20 μm (d). (e, f) The quantitation of the 
number of TBR1+ EX and GAD1+ IN neurons with tau inclusions (n = 80 region of 
interests (ROI) from 4 coverslips per group). (b, e and f) Data are presented as mean ± SEM. 
Statistical significance was assessed by nonparametric Kruskal-Wallis test with the post hoc 
test of Dunn’s multiple comparisons. *** P < 0.0001 vs neurons transduced with scramble 
BAG3 (The Kruskal-Wallis statistic is 34.54, 164.6 and 20.09, respectively.).
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